Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P00505
UPID:
AATM_HUMAN
Alternative names:
Fatty acid-binding protein; Glutamate oxaloacetate transaminase 2; Kynurenine aminotransferase 4; Kynurenine aminotransferase IV; Kynurenine--oxoglutarate transaminase 4; Kynurenine--oxoglutarate transaminase IV; Plasma membrane-associated fatty acid-binding protein; Transaminase A
Alternative UPACC:
P00505; B4DJA6; E7ERW2; Q53FL3; Q9BWA3
Background:
Aspartate aminotransferase, mitochondrial, also known by its alternative names such as Fatty acid-binding protein and Kynurenine aminotransferase IV, plays a pivotal role in amino acid metabolism and the intracellular NAD(H) redox balance. It catalyzes the conversion of L-kynurenine to kynurenic acid, a critical step in the tryptophan metabolism pathway.
Therapeutic significance:
The protein's involvement in Developmental and epileptic encephalopathy 82, a severe early-onset epilepsy, underscores its potential as a target for therapeutic intervention. Understanding the role of Aspartate aminotransferase, mitochondrial could open doors to potential therapeutic strategies.